查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095662

mRNA治療藥物市場－2026-2032年全球市場預測

mRNA Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，mRNA 療法市場將成長至 270.5 億美元，複合年成長率為 13.23%。

主要市場統計數據
基準年 2025 113.3億美元
預計年份：2026年 125.8億美元
預測年份 2032 270.5億美元
複合年成長率 (%) 13.23%

在核苷修飾、脂質奈米顆粒遞送、可擴展的體外轉錄和改進的分析表徵等技術的推動下，mRNA療法已從一個利基平台發展成為現代生物製藥創新的核心支柱。此領域涵蓋預防性疫苗、癌症免疫療法、蛋白質替代療法、基因編輯輔助、再生醫學以及罕見疾病和感染疾病的治療。其戰略價值在於其「可程式設計」——也就是說，一旦確定了目標抗原或蛋白質序列，開發人員就可以比許多傳統生技藥品更快地迭代候選藥物。從已通過核准的mRNA疫苗中獲得的監管經驗提高了人們對品管、藥物安全監測、低溫運輸管理和風險效益評估的期望。隨著相關人員尋求能夠應對新出現的病原體、滿足個人化癌症治療需求以及治療以往無法治癒的標靶的平台，mRNA療法正日益成為精準醫療和下一代生物製藥領域極具影響力的療法。

mRNA治療領域的變革性變化

mRNA療法領域正因遞送系統的改進、生產柔軟性的提升以及臨床應用的多元化而發生重塑。儘管脂質奈米顆粒仍然是最成熟的遞送載體，但對定向製劑、聚合物載體和組織選擇性遞送方法的研究正在不斷拓展，旨在提高耐受性並實現除肝臟和免疫系統以外的其他給藥途徑。自擴增RNA、環狀RNA和最佳化的非翻譯區域因其延長表達週期、降低劑量和延長治療持續時間的潛力而備受關注。生產製造也在向模組化、自動化和地理分散的生產系統轉變，從而減少對集中式生產的依賴，並支持對感染疾病爆發的快速反應。在臨床方面，該領域的應用範圍正從大流行疫苗擴展到個人化癌症疫苗、呼吸道病毒聯合治療、自體免疫調節、罕見疾病中的蛋白質表現以及體內基因編輯的實現。這些變化正在建立一個更複雜但更具韌性的生態系統，其中平台設計、遞送精度、監管準備和供應鏈可靠性正成為關鍵的競爭因素。

人工智慧對mRNA療法的累積影響

人工智慧 (AI) 透過改善標靶發現、序列設計、製劑最佳化、臨床試驗規劃和上市後安全性監測，加速了 mRNA 療法的開發。機器學習模型透過支持抗原選擇、表位預測、密碼子最佳化、二級結構評估和免疫抗原性評估，幫助研究人員在實驗室檢驗前最佳化候選藥物。在遞送研究方面，AI 驅動的建模能夠評估大規模實驗資料集中的脂質組成、顆粒穩定性、生物分佈訊號和生產製程參數。在臨床開發方面，資料科學工具正在改善患者分層、生物標記選擇、研究中心規劃和適應性試驗設計，尤其是在臨床實驗和罕見疾病等異質性領域。 AI 也透過偵測真實世界數據、註冊登記和安全性報告中的不利事件模式，加強了藥物安全性監測。雖然這些功能可以降低實驗門檻，但它們的累積效應取決於透明的模型檢驗、高品質的生物資料集、符合監管標準的文檔以及防止偏倚的措施。將人工智慧與實驗室測試、臨床證據的生成以及穩健的品質設計（QbD）實踐相結合，有望取得最佳結果。

mRNA療法的關鍵區域見解

mRNA療法的區域發展趨勢反映了科學基礎設施、監管成熟度、生產能力、公共衛生優先事項以及生物技術投資方面的差異。亞太地區正透過擴大疫苗生產、加強臨床研究網路以及中國、日本、韓國、澳洲、印度和東協市場優先考慮疫情防範和生物製藥自給自足的國家舉措，不斷提升自身地位。北美地區憑藉先進的學術研究、成熟的監管流程、強大的臨床試驗基礎設施以及對癌症、感染疾病和罕見疾病領域創新療法的強勁需求，仍然保持著高度活躍的態勢。拉丁美洲在疫苗取得、本地灌裝和包裝能力、感染疾病監測以及公私合營發揮著日益重要的作用，其中巴西和墨西哥已成為該地區臨床開發和生產夥伴關係的關鍵樞紐。歐洲受益於協調一致的監管專業知識、強大的轉化科學和跨境研究項目，同時優先考慮品質、安全監測和穩健的供應鏈。在中東，生物技術能力正透過醫療現代化、政府投資和生命科學基礎設施建設而逐步提升，尤其需要在海灣國家建立區域性生產和臨床研究能力。非洲mRNA療法的發展機會與疫苗的公平分配、技術轉移、人力資源開發、疾病監測和本地生產能力密切相關，而人們日益認知到，區域性生產將有助於更好地應對感染疾病疫情，並增強長期的健康安全。

RSA治療藥物的關鍵組別分析

集團層面的趨勢表明，政策協調、貿易關係、衛生安全優先事項和科學合作如何影響mRNA療法的引入和發展。東南亞國協致力於提升區域衛生韌性、加強監管合作、保障疫苗取得以及建立生物製造夥伴關係，以支持東南亞地區對感染疾病威脅的快速反應。海灣合作理事會成員國正透過投資生物技術園區、精準醫療計畫、臨床研究能力和本地製造計劃，推動醫療保健多元化，使該地區成為先進療法的新興中心。歐盟透過協調一致的法律規範、跨境資金籌措機制、藥物安全監測系統和公共衛生框架，為mRNA研究提供了高度結構化的環境。金磚國家透過強調大規模的患者群體、不斷擴大的科學人才隊伍、公共衛生領域的製造經驗以及國內生物製藥能力等政策，發揮關鍵作用。七國集團（G7）國家繼續透過監管領導、先進的研發生態系統、全球衛生資金以及以快速疫苗和治療回應為重點的準備策略，推動mRNA療法的發展。北約成員國越來越將生物技術供應鏈、醫療保健應對和疫情應對能力視為更廣泛的衛生安全和韌性計劃的一部分，這進一步提高了mRNA平台在其國家準備框架中的戰略重要性。

主要國家mRNA治療藥物的發展趨勢

國別分析突顯了影響mRNA療法研發和應用的多元化路徑。美國在轉化研究深度、臨床試驗密度、監管經驗和先進製造技術方面處於主導，並在感染疾病、腫瘤、罕見疾病和基因編輯應用領域積極開展工作。加拿大憑藉著卓越的學術水平、公共衛生準備和對國內生物製造能力的投資做出貢獻。墨西哥透過參與臨床試驗、在區域製造領域的重要性以及與北美供應鏈的接近性，其重要性日益提升。巴西憑藉其公共衛生機構、疫苗生產經驗和感染疾病研究能力，在拉丁美洲發揮關鍵作用。英國在基因組醫學領域處於領先地位，擁有臨床研究網路和柔軟性的監管政策，支持先進療法的研發。德國是歐洲領先的生物技術中心，在RNA科學、製造工程和轉化醫學方面實力雄厚，而法國則專注於生物醫學研究、疫苗政策和醫療保健創新。俄羅斯在免疫學和疫苗研究方面保持著強大的科研實力，但其獲取國際合作和技術的機會受到地緣政治制約。義大利和西班牙透過臨床研究網路、醫院臨床試驗基礎設施以及對腫瘤和感染疾病應用日益成長的興趣做出貢獻。中國正透過開發國內平台、擴大生產規模和進行大規模生物醫學研究項目，快速推動mRNA療法的發展。印度憑藉其在疫苗生產方面的專業知識、成本效益高的生產能力以及對擴大生物技術政策的支持，發揮關鍵作用。日本在精準醫療、監管科學和高品質臨床研究方面表現卓越，而澳洲則透過其強大的研究機構和高效的臨床試驗環境，為早期臨床開發提供支援。韓國正透過大力投資生物製造、疫苗自主研發和先進療法基礎設施，鞏固其在亞太mRNA生態系統中的地位。

為mRNA療法領域的領導者提供的實用建議

產業領導者應優先考慮遞送技術創新、生產韌性和證據生成，以負責任的方式推進mRNA療法的發展。首先，投資組織標靶遞送系統和製劑分析，以提高安全性、耐受性和治療精準度，使其超越疫苗應用。其次，建構靈活的生產平台，確保原料來源經過檢驗，有效控制污染，低溫運輸替代方案，並具備快速切換能力。第三，儘早整合品質源自於設計（QbD）原則，包括關鍵品質屬性的映射、療效評估、穩定性測試和等效性策略。第四，在可重複的實驗和臨床證據檢驗的領域，選擇性地應用人工智慧和自動化技術。第五，加強與監管機構的合作，使研發計畫與不斷更新的RNA表徵、遞送系統、免疫抗原性和長期安全性監測指南保持一致。第六，拓展臨床開發模式，納入多樣化的受試者群體、分佈式要素、基於生物標記的受試者招募以及真實世界數據（REW）的收集。最後，我們致力於負責任的技術轉移和本地夥伴關係，以提高公平獲取的機會，同時保護品質、生物安全和供應鏈完整性。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，重點在於檢驗且有數據支持的產業證據。資訊來源包括同行評審的科學文獻、監管指南和評估文件、臨床試驗註冊資訊、公共衛生機構出版刊物、專利和技術趨勢綜述、國家生物技術政策文件，以及來自經認證的醫療保健和生命科學機構的檢驗資訊。調查方法強調“三角驗證”，即交叉引用科學、監管和政策資訊來源，以識別在給藥技術、臨床開發、生產製造、區域產能和衛生安全相關性等方面的反覆出現的趨勢。雖然採用定性分析來評估策略轉變，但並未提供市場規模、市場佔有率、市場估值或預測。區域、群體和國家層面的洞察來自已記錄的基礎設施、政策重點、臨床研究活動、生產工作和公共衛生需求。研究過程優先考慮資訊來源的可靠性、及時性、可追溯性和一致性，同時避免未經證實的說法和宣傳性定位。

結論

mRNA療法正邁向一個更廣泛、技術更先進的階段，從緊急疫苗反應發展成為一個多元化的平台，應用於精準醫療、癌症治療、感染疾病預防、罕見疾病治療和基因編輯等領域。未來的進展取決於克服遞送限制、提高生產可靠性、改善穩定性和可近性，以及在不同的治療領域中獲得嚴謹的臨床證據。區域和國家層級在生物製造、監管能力和衛生安全方面的投資正在進一步分散這一生態系統，而人工智慧和先進的分析技術則提高了藥物發現和開發的速度和準確性。擁有嚴謹的科學態度、可擴展的生產系統、透明的安全監測和公平的獲取策略的利益相關人員，將最有能力塑造mRNA療法的未來。隨著這些療法的成熟，其長期影響不僅取決於研發速度，還取決於已證實的患者獲益、可靠的品管體係以及與全球醫療基礎設施的永續整合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 mRNA治療市場：依產品類型分類

  • 預防性mRNA疫苗
    • 感染疾病疫苗
    • 大流行疫苗
    • 季節性疫苗
  • 治療性mRNA藥物
    • 腫瘤免疫療法
    • 蛋白質替代療法
    • 基因編輯與編碼療法
    • 體內細胞編程療法
    • 免疫調節療法
    • 再生/組織修復療法

第8章 mRNA治療藥物市場：依遞送技術分類

  • 脂質奈米顆粒遞送系統
  • 基於聚合物的遞送系統
  • 脂質體聚合物遞送系統
  • 基於胜肽的遞送系統
  • 利用病毒載體的遞送系統
  • 裸露的mRNA遞送系統

第9章 mRNA 治療市場：依編碼分子類型分類

  • 抗原編碼mRNA
  • 編碼細胞激素的mRNA
  • 抗體編碼的mRNA
  • 酵素編碼mRNA
  • 生長因子編碼mRNA
  • 編碼基因編輯組分的mRNA

第10章 mRNA治療市場：以mRNA類型分類

  • 常規非複製型mRNA
  • 自擴增mRNA
  • 環狀RNA療法
  • 反式擴增的mRNA

第11章 mRNA治療藥物市場：依給藥途徑分類

  • 肌肉內注射
  • 靜脈注射
  • 皮內給藥
  • 皮下注射
  • 鼻內給藥
  • 瘤內給藥

第12章 mRNA治療藥物市場：依治療領域分類

  • 心血管系統
  • 感染疾病
  • 腫瘤學
  • 罕見疾病
  • 自體免疫疾病
  • 神經病變
  • 呼吸系統疾病
  • 再生醫學

第13章 mRNA治療市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 學術研究機構
  • 生技公司
  • 製藥公司
  • 受託研究機構

第14章 mRNA治療藥物市場：依研發階段分類

  • 藥物發現階段
  • 臨床前階段
  • 臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 市售產品

第15章 mRNA治療藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 mRNA 治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 mRNA 治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc.
  • Abogen Biosciences Co., Ltd.
  • Acuitas Therapeutics Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CanSino Biologics Inc.
  • Carisma Therapeutics Inc.
  • Cartesian Therapeutics, Inc.
  • CSL Limited
  • CSPC Pharmaceutical Group Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Entos Pharmaceuticals Inc.
  • Esperovax, Inc.
  • eTheRNA immunotherapies NV
  • Ethris GmbH
  • GSK plc
  • HDT Bio Corp.
  • Intellia Therapeutics, Inc.
  • Kernal Biologics, Inc.
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Nutcracker Therapeutics, Inc.
  • Pfizer Inc.
  • Providence Therapeutics Holdings Inc.
  • ReCode Therapeutics, Inc.
  • Replicate Bioscience, Inc.
  • Sanofi SA
  • Stemirna Therapeutics Co., Ltd.
  • Strand Therapeutics, Inc.
  • Tessera Therapeutics, Inc.
  • Tiba Biotech LLC
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-205091A88BBD

The mRNA Therapeutics Market is projected to grow by USD 27.05 billion at a CAGR of 13.23% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.33 billion
Estimated Year [2026] USD 12.58 billion
Forecast Year [2032] USD 27.05 billion
CAGR (%) 13.23%

mRNA therapeutics have moved from a specialist platform into a central pillar of modern biopharmaceutical innovation, supported by advances in nucleoside modification, lipid nanoparticle delivery, scalable in vitro transcription, and improved analytical characterization. The field spans prophylactic vaccines, cancer immunotherapy, protein replacement, gene editing support, regenerative medicine, and treatments for rare and infectious diseases. Its strategic value lies in programmability: once a target antigen or protein sequence is defined, developers can design, manufacture, and iterate candidates faster than many conventional biologics. Regulatory experience gained from authorized mRNA vaccines has strengthened expectations around quality controls, pharmacovigilance, cold-chain management, and benefit-risk assessment. As stakeholders seek platforms that can respond to emerging pathogens, personalized oncology needs, and previously undruggable targets, mRNA therapeutics are increasingly positioned as a high-impact modality within precision medicine and next-generation biologics.

Transformative Shifts in the mRNA Therapeutics Landscape

The mRNA therapeutics landscape is being reshaped by improvements in delivery systems, manufacturing flexibility, and clinical application diversity. Lipid nanoparticles remain the most established delivery vehicle, but research is expanding into targeted formulations, polymeric carriers, and tissue-selective delivery approaches to improve tolerability and enable administration beyond the liver and immune system. Self-amplifying RNA, circular RNA, and optimized untranslated regions are gaining attention for their potential to extend expression, reduce dose requirements, and improve therapeutic durability. Manufacturing is also shifting toward modular, automated, and geographically distributed capacity, helping reduce dependency on centralized production and supporting faster outbreak response. Clinically, the sector is broadening from pandemic-driven vaccines toward individualized cancer vaccines, respiratory virus combinations, autoimmune modulation, rare disease protein expression, and in vivo gene editing enablement. These shifts are creating a more complex but more resilient ecosystem in which platform design, delivery precision, regulatory readiness, and supply-chain reliability are becoming decisive competitive factors.

Cumulative Impact of Artificial Intelligence on mRNA Therapeutics

Artificial intelligence is accelerating mRNA therapeutics by improving target discovery, sequence design, formulation optimization, clinical trial planning, and post-market safety monitoring. Machine learning models support antigen selection, epitope prediction, codon optimization, secondary structure assessment, and immunogenicity risk evaluation, helping researchers refine candidates before laboratory validation. In delivery research, AI-enabled modeling can evaluate lipid composition, particle stability, biodistribution signals, and manufacturability parameters across large experimental datasets. In clinical development, data science tools improve patient stratification, biomarker selection, site activation planning, and adaptive trial design, particularly in oncology and rare diseases where patient populations are heterogeneous. AI also strengthens pharmacovigilance by detecting adverse event patterns across real-world data, registries, and safety reports. While these capabilities can reduce experimental friction, the cumulative impact depends on transparent model validation, high-quality biological datasets, regulatory-grade documentation, and safeguards against bias. The strongest outcomes are expected where AI is integrated with wet-lab testing, clinical evidence generation, and robust quality-by-design practices.

Key Regional Insights for mRNA Therapeutics

Regional dynamics in mRNA therapeutics reflect differences in scientific infrastructure, regulatory maturity, manufacturing capacity, public health priorities, and investment in biotechnology. Asia-Pacific is strengthening its role through expanding vaccine manufacturing, growing clinical research networks, and national initiatives in China, Japan, South Korea, Australia, India, and ASEAN markets that prioritize pandemic preparedness and biopharmaceutical self-reliance. North America remains highly active due to advanced academic research, mature regulatory pathways, deep clinical trial infrastructure, and strong demand for oncology, infectious disease, and rare disease innovation. Latin America is increasingly relevant for vaccine access, local fill-finish capabilities, infectious disease surveillance, and public-private collaboration, with Brazil and Mexico serving as important anchors for regional clinical development and manufacturing partnerships. Europe benefits from coordinated regulatory expertise, strong translational science, and cross-border research programs, while emphasizing quality, safety monitoring, and resilient supply chains. The Middle East is building biotechnology capabilities through healthcare modernization, sovereign investment, and life sciences infrastructure, particularly in Gulf economies seeking regional manufacturing and clinical research capabilities. Africa's mRNA therapeutics opportunity is closely tied to vaccine equity, technology transfer, workforce development, disease surveillance, and localized production capacity, supported by growing recognition that regional manufacturing can improve outbreak response and long-term health security.

Key Group Insights for mRNA Therapeutics

Group-level dynamics show how policy alignment, trade relationships, health security priorities, and scientific collaboration influence mRNA therapeutics adoption and development. ASEAN countries are focusing on regional health resilience, regulatory cooperation, vaccine access, and biomanufacturing partnerships that can support faster response to infectious disease threats across Southeast Asia. GCC members are advancing healthcare diversification through investment in biotechnology parks, precision medicine programs, clinical research capacity, and local manufacturing ambitions, positioning the region as an emerging hub for advanced therapeutics. The European Union provides a highly structured environment for mRNA research through harmonized regulatory oversight, cross-border funding mechanisms, pharmacovigilance systems, and coordinated public health frameworks. BRICS countries bring substantial relevance through large patient populations, expanding scientific talent, public health manufacturing experience, and policy emphasis on domestic biopharmaceutical capability. G7 countries continue to shape mRNA therapeutics through regulatory leadership, advanced R&D ecosystems, global health financing, and preparedness strategies focused on rapid vaccine and therapeutic response. NATO-aligned countries increasingly view biotechnology supply chains, medical countermeasures, and pandemic response capacity as part of broader health security and resilience planning, reinforcing the strategic importance of mRNA platforms in national preparedness frameworks.

Key Country Insights for mRNA Therapeutics

Country-level insights highlight the diverse pathways shaping mRNA therapeutics development and access. The United States leads in translational research depth, clinical trial density, regulatory experience, and advanced manufacturing know-how, with strong activity across infectious disease, oncology, rare diseases, and gene editing applications. Canada contributes through academic excellence, public health preparedness, and investments in domestic biomanufacturing capacity. Mexico is gaining importance through clinical trial participation, regional manufacturing relevance, and proximity to North American supply chains. Brazil plays a major role in Latin America through public health institutions, vaccine production experience, and infectious disease research capacity. The United Kingdom combines genomic medicine leadership, clinical research networks, and regulatory agility that support advanced therapeutic development. Germany is a major European biotechnology center with strengths in RNA science, manufacturing engineering, and translational medicine, while France emphasizes biomedical research, vaccine policy, and healthcare innovation. Russia maintains scientific capacity in immunology and vaccine research, although international collaboration and technology access are influenced by geopolitical constraints. Italy and Spain contribute through clinical research networks, hospital-based trial infrastructure, and growing interest in oncology and infectious disease applications. China is rapidly advancing mRNA therapeutics through domestic platform development, manufacturing scale-up, and large biomedical research programs. India is important for vaccine manufacturing expertise, cost-efficient production capabilities, and expanding biotechnology policy support. Japan brings strengths in precision medicine, regulatory science, and high-quality clinical research, while Australia supports early-stage clinical development through strong research institutions and an efficient trial environment. South Korea is investing heavily in biomanufacturing, vaccine sovereignty, and advanced therapy infrastructure, strengthening its position in the Asia-Pacific mRNA ecosystem.

Actionable Recommendations for mRNA Therapeutics Leaders

Industry leaders should prioritize delivery innovation, manufacturing resilience, and evidence generation to advance mRNA therapeutics responsibly. First, invest in tissue-targeted delivery systems and formulation analytics that improve safety, tolerability, and therapeutic precision beyond vaccine applications. Second, build flexible manufacturing platforms with validated raw material sourcing, contamination controls, cold-chain alternatives, and rapid changeover capabilities. Third, integrate quality-by-design principles early, including critical quality attribute mapping, potency assays, stability testing, and comparability strategies. Fourth, use AI and automation selectively where they can be validated through reproducible experimental and clinical evidence. Fifth, strengthen regulatory engagement by aligning development plans with evolving guidance on RNA characterization, delivery systems, immunogenicity, and long-term safety monitoring. Sixth, expand clinical development models that include diverse populations, decentralized elements, biomarker-driven enrollment, and real-world evidence collection. Finally, pursue responsible technology transfer and regional partnerships that improve equitable access while protecting quality, biosafety, and supply-chain integrity.

Research Methodology

This executive summary is developed through a structured secondary research approach focused on verified, data-backed industry evidence. Inputs include peer-reviewed scientific literature, regulatory guidance and assessment documents, clinical trial registries, public health agency publications, patent and technology trend reviews, national biotechnology policy documents, and validated information from recognized healthcare and life sciences institutions. The methodology emphasizes triangulation across scientific, regulatory, and policy sources to identify recurring trends in delivery technology, clinical development, manufacturing, regional capability, and health security relevance. Qualitative analysis is used to assess strategic shifts without presenting market sizing, market share, market estimation, or forecasting. Regional, group, and country insights are synthesized from documented infrastructure, policy priorities, clinical research activity, manufacturing initiatives, and public health needs. The research process prioritizes source credibility, recency, traceability, and consistency, while avoiding unsupported claims and promotional positioning.

Conclusion

mRNA therapeutics are entering a broader and more technically sophisticated phase, moving beyond emergency vaccine response into a diversified platform for precision medicine, cancer therapy, infectious disease prevention, rare disease treatment, and gene editing enablement. The next stage of progress will depend on resolving delivery limitations, strengthening manufacturing reliability, improving stability and access, and generating rigorous clinical evidence across varied therapeutic areas. Regional and national investments in biomanufacturing, regulatory capacity, and health security are making the ecosystem more distributed, while AI and advanced analytics are improving the speed and precision of discovery and development. Stakeholders that combine scientific rigor, scalable production, transparent safety monitoring, and equitable access strategies will be best positioned to shape the future of mRNA therapeutics. As the modality matures, its long-term impact will be defined not only by speed of design but by demonstrable patient benefit, trusted quality systems, and sustainable integration into global healthcare infrastructure.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. mRNA Therapeutics Market, by Product Type

  • 7.1. Introduction
  • 7.2. Prophylactic mRNA Vaccines
    • 7.2.1. Infectious Disease Vaccines
    • 7.2.2. Pandemic Preparedness Vaccines
    • 7.2.3. Seasonal Vaccines
  • 7.3. Therapeutic mRNA Medicines
    • 7.3.1. Oncology Immunotherapies
    • 7.3.2. Protein Replacement Therapies
    • 7.3.3. Gene Editing-Encoding Therapies
    • 7.3.4. In Vivo Cell Programming Therapies
    • 7.3.5. Immune Modulation Therapies
    • 7.3.6. Regenerative And Tissue Repair Therapies

8. mRNA Therapeutics Market, by Delivery Technology

  • 8.1. Introduction
  • 8.2. Lipid Nanoparticle Delivery Systems
  • 8.3. Polymer-Based Delivery Systems
  • 8.4. Lipopolyplex Delivery Systems
  • 8.5. Peptide-Based Delivery Systems
  • 8.6. Viral Vector-Assisted Delivery Systems
  • 8.7. Naked mRNA Delivery Systems

9. mRNA Therapeutics Market, by Molecule Encoding Type

  • 9.1. Introduction
  • 9.2. Antigen-Encoding mRNA
  • 9.3. Cytokine-Encoding mRNA
  • 9.4. Antibody-Encoding mRNA
  • 9.5. Enzyme-Encoding mRNA
  • 9.6. Growth Factor-Encoding mRNA
  • 9.7. Gene Editing Component-Encoding mRNA

10. mRNA Therapeutics Market, by mRNA Type

  • 10.1. Introduction
  • 10.2. Conventional Non-Replicating mRNA
  • 10.3. Self-Amplifying mRNA
  • 10.4. Circular RNA Therapeutics
  • 10.5. Trans-Amplifying mRNA

11. mRNA Therapeutics Market, by Route Of Administration

  • 11.1. Introduction
  • 11.2. Intramuscular Administration
  • 11.3. Intravenous Administration
  • 11.4. Intradermal Administration
  • 11.5. Subcutaneous Administration
  • 11.6. Intranasal Administration
  • 11.7. Intratumoral Administration

12. mRNA Therapeutics Market, by Therapeutic Area

  • 12.1. Introduction
  • 12.2. Cardiovascular
  • 12.3. Infectious Diseases
  • 12.4. Oncology
  • 12.5. Rare Diseases
  • 12.6. Autoimmune Diseases
  • 12.7. Neurological Disorders
  • 12.8. Respiratory Diseases
  • 12.9. Regenerative Medicine

13. mRNA Therapeutics Market, by End User

  • 13.1. Introduction
  • 13.2. Hospitals
  • 13.3. Specialty Clinics
  • 13.4. Academic & Research Institutes
  • 13.5. Biotechnology Companies
  • 13.6. Pharmaceutical Companies
  • 13.7. Contract Research Organizations

14. mRNA Therapeutics Market, by Development Stage

  • 14.1. Introduction
  • 14.2. Discovery Stage
  • 14.3. Preclinical Stage
  • 14.4. Clinical Stage
    • 14.4.1. Phase I
    • 14.4.2. Phase II
    • 14.4.3. Phase III
  • 14.5. Commercialized Products

15. mRNA Therapeutics Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. mRNA Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. mRNA Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2025
  • 18.2. FPNV Positioning Matrix, 2025
  • 18.3. Market Concentration Analysis, 2025
    • 18.3.1. Concentration Ratio (CR)
    • 18.3.2. Herfindahl Hirschman Index (HHI)
  • 18.4. Recent Developments & Impact Analysis, 2025
  • 18.5. Product Portfolio Analysis, 2025
  • 18.6. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc.
  • 19.2. Abogen Biosciences Co., Ltd.
  • 19.3. Acuitas Therapeutics Inc.
  • 19.4. Arcturus Therapeutics Holdings Inc.
  • 19.5. Beam Therapeutics Inc.
  • 19.6. BioNTech SE
  • 19.7. CanSino Biologics Inc.
  • 19.8. Carisma Therapeutics Inc.
  • 19.9. Cartesian Therapeutics, Inc.
  • 19.10. CSL Limited
  • 19.11. CSPC Pharmaceutical Group Limited
  • 19.12. Daiichi Sankyo Company, Limited
  • 19.13. Eli Lilly and Company
  • 19.14. Entos Pharmaceuticals Inc.
  • 19.15. Esperovax, Inc.
  • 19.16. eTheRNA immunotherapies NV
  • 19.17. Ethris GmbH
  • 19.18. GSK plc
  • 19.19. HDT Bio Corp.
  • 19.20. Intellia Therapeutics, Inc.
  • 19.21. Kernal Biologics, Inc.
  • 19.22. Meiji Holdings Co., Ltd.
  • 19.23. Merck & Co., Inc.
  • 19.24. Moderna, Inc.
  • 19.25. Nutcracker Therapeutics, Inc.
  • 19.26. Pfizer Inc.
  • 19.27. Providence Therapeutics Holdings Inc.
  • 19.28. ReCode Therapeutics, Inc.
  • 19.29. Replicate Bioscience, Inc.
  • 19.30. Sanofi SA
  • 19.31. Stemirna Therapeutics Co., Ltd.
  • 19.32. Strand Therapeutics, Inc.
  • 19.33. Tessera Therapeutics, Inc.
  • 19.34. Tiba Biotech LLC
  • 19.35. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MRNA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 29. GLOBAL MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROPHYLACTIC MRNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROPHYLACTIC MRNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROPHYLACTIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PANDEMIC PREPAREDNESS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PANDEMIC PREPAREDNESS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PANDEMIC PREPAREDNESS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEASONAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEASONAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEASONAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC MRNA MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC MRNA MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC MRNA MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROTEIN REPLACEMENT THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROTEIN REPLACEMENT THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROTEIN REPLACEMENT THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE EDITING-ENCODING THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING-ENCODING THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING-ENCODING THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN VIVO CELL PROGRAMMING THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN VIVO CELL PROGRAMMING THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN VIVO CELL PROGRAMMING THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNE MODULATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNE MODULATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNE MODULATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL REGENERATIVE AND TISSUE REPAIR THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL REGENERATIVE AND TISSUE REPAIR THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL REGENERATIVE AND TISSUE REPAIR THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIPID NANOPARTICLE DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIPID NANOPARTICLE DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIPID NANOPARTICLE DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POLYMER-BASED DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POLYMER-BASED DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POLYMER-BASED DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIPOPOLYPLEX DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIPOPOLYPLEX DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIPOPOLYPLEX DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE-BASED DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE-BASED DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE-BASED DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTOR-ASSISTED DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTOR-ASSISTED DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTOR-ASSISTED DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NAKED MRNA DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NAKED MRNA DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NAKED MRNA DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIGEN-ENCODING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIGEN-ENCODING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIGEN-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYTOKINE-ENCODING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYTOKINE-ENCODING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYTOKINE-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBODY-ENCODING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBODY-ENCODING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBODY-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENZYME-ENCODING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENZYME-ENCODING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENZYME-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GROWTH FACTOR-ENCODING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GROWTH FACTOR-ENCODING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GROWTH FACTOR-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE EDITING COMPONENT-ENCODING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE EDITING COMPONENT-ENCODING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE EDITING COMPONENT-ENCODING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CONVENTIONAL NON-REPLICATING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONVENTIONAL NON-REPLICATING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CONVENTIONAL NON-REPLICATING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SELF-AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CIRCULAR RNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CIRCULAR RNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CIRCULAR RNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANS-AMPLIFYING MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TRANS-AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANS-AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRAMUSCULAR ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INTRAMUSCULAR ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRAMUSCULAR ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRAVENOUS ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRAVENOUS ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRAVENOUS ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SUBCUTANEOUS ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SUBCUTANEOUS ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SUBCUTANEOUS ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRANASAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRANASAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRANASAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRATUMORAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRATUMORAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTRATUMORAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RESPIRATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DISCOVERY STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DISCOVERY STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DISCOVERY STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL PRECLINICAL STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CLINICAL STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CLINICAL STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CLINICAL STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL COMMERCIALIZED PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL COMMERCIALIZED PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL COMMERCIALIZED PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. GCC MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 262. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 263. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GCC MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. GCC MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. GCC MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 270. GCC MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. G7 MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 298. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 299. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. G7 MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. G7 MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. G7 MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 304. G7 MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. G7 MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 306. G7 MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 307. NATO MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. NATO MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. NATO MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 310. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 311. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. NATO MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. NATO MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 316. NATO MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. NATO MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 318. NATO MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 319. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA MRNA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA MRNA THERAPEUTICS MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 344. MEXICO MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY PROPHYLACTIC MRNA VACCINES, 2018-2032 (USD MILLION)
  • TABLE 347. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MRNA MEDICINES, 2018-2032 (USD MILLION)
  • TABLE 348. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY MOLECULE ENCODING TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY MRNA TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 352. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 353. MEXICO MRNA T